Cite
HARVARD Citation
Piedra, K. et al. (2022). Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. British journal of haematology. pp. 105-109. [Online].